Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript Summary
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript Summary
Net loss for the quarter was significantly reduced to $25.5 million, or $0.10 per share, compared to a net loss of $117.1 million, or $0.93 per share, in Q3 2023.The following is a summary of the Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript:
以下是泰莎基因治療公司（TSHA）2024年第三季度業績會交易摘要：
Financial Performance:
財務表現:
Research and development expenses increased to $14.9 million for Q3 2024 compared to $11.8 million in Q3 2023.
General and administrative expenses decreased to $7.9 million in Q3 2024 from $8.6 million in the same period last year.
Net loss for the quarter was significantly reduced to $25.5 million, or $0.10 per share, compared to a net loss of $117.1 million, or $0.93 per share, in Q3 2023.
研發費用在2024年第三季度增至1490萬美元，而去年同期爲1180萬美元。
2024年第三季度的一般和管理費用從去年同期的860萬美元降至790萬美元。
該季度的淨虧損明顯降至2550萬美元，每股虧損0.10美元，而在2023年第三季度爲淨虧損11710萬美元，每股虧損0.93美元。
Business Progress:
業務進展：
Advanced the TSHA-102 gene therapy program targeting Rett Syndrome, with significant ongoing clinical trials.
Successfully completed a pivotal Type D CMC meeting with the FDA, securing approval to use the pivotal TSHA-102 product in REVEAL trials based on demonstrated analytical comparability.
Recent positive interactions with the FDA, including a productive RMAT Type B multidisciplinary meeting, could expedite the development plan for TSHA-102.
推進了旨在治療雷特氏綜合徵的TSHA-102基因治療項目，並進行了重要的臨床試驗。
成功完成了與FDA的關鍵D型CMC會議，獲得批准在REVEAL試驗中使用關鍵的TSHA-102產品，基於展示的分析比較性。
最近與FDA的積極互動，包括富有成效的RMAt Type b跨學科會議，可能加快TSHA-102的開發計劃。
Opportunities:
機會：
Rett Syndrome treatment shows market potential with TSHA-102's promising results and RMAT designation. The pediatric and adult REVEAL trials highlight TSHA-102 as a potential minimally invasive gene therapy solution for a range of patients.
TSHA-102有望在萊特氏綜合症治療市場中展現出潛力，並且RMAt認證。兒科和成人REVEAL試驗突顯TSHA-102作爲一種可能的微創基因療法解決方案，適用於一系列患者。
Risks:
風險：
The ongoing safety and efficacy evaluations still pose risks, particularly with changes or negative outcomes in long-term data.
持續進行的安全性和有效性評估仍存在風險，特別是長期數據發生變化或出現負面結果。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
